|
TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced financial results for the second quarter ended June 30, 2021 and provided a business update.
“The second quarter of 2021 was marked mainly by the timely approval of our liposomal amphotericin B product in India and the immediate partnerships for their commercialization and sales in the territory,” commented George Yeh, President of TLC. “We are grateful to have the ability to be of assistance in this humanitarian crisis brought about by the COVID-19 pandemic by fulfilling an unmet need, and will continue our quest to provide best-in-class treatments in pain management, ophthalmology, oncology, as well as infectious diseases.”
Clinical Pipeline Update and Upcoming Milestones
- All subjects have reached the 24-week timepoint in EXCELLENCE. The Phase III pivotal clinical trial of TLC599 in ~500 subjects is progressing smoothly, with all subject having reached the 24-week timepoint and the majority of whom having received the second injection of either TLC599 or placebo. There remains no safety concerns or serious adverse events related to treatment. The multi-center, randomized, double-blind, active comparator- and placebo-controlled pivotal study is evaluating the efficacy and safety of a single and a repeat dose of TLC599 in patients with knee osteoarthritis across 46 sites in the United States and Australia.
- Pivotal clinical trial of TLC590 to kick off soon. Following a fruitful End-of-Phase 2 meeting with the United States Food and Drug Administration (FDA), TLC has accrued additional guidelines on the design parameters for the pivotal clinical trials of TLC590 for post-operative pain and will be kicking off the next trial soon.
- Liposomal amphotericin B receives approval in India. The Central Drugs Standard Control Organization (CDSCO) of India approved the New Drug Application (NDA) of Amphotericin B Liposome for Injection 50mg (known as Ampholipad® in Taiwan and AmphoTLC™ in India). The registration allows for immediate importation per approved usage and indication to aid in the country’s acute shortage of treatments for COVID-19 associated mucormycosis.
- Presented data on advantages of inhalable liposome formulations of antiviral drugs for lung diseases at ISAM. At the 23rd International Society for Aerosols in Medicine (ISAM) Congress, TLC’s subsidiary, InspirMed, presented data from pharmacokinetic studies on ISPM21 (inhalable liposomal GS-441524, main plasma metabolite of remdesivir), and ISPM19 (inhalable liposomal hydroxychloroquine) that showed significantly higher concentrations in the lungs than their conventional counterparts, suggesting feasibility of higher dosing without hepatotoxicity or nephrotoxicity as an improvement upon current treatments.
Corporate Highlights
- Commercialization of liposomal amphotericin B in India. Following the new drug registration, TLC entered non-exclusive partnerships with Zydus Healthcare Limited and Strides Pharma Science Limited to begin immediate distribution of its liposomal amphotericin B product in India.
- Partnership with Endo International plc for the commercialization of a liposomal product. TLC is eligible to receive upfront and subsequent milestone payments as well as a double-digit share of the net profits from product sales in the United States.
- Stock swap and restructuring. Details of the share swap transactions and restructuring with Woods Investment Company, along with a list of frequently asked questions, can be found on the company website (tlcbio.com) under Investors/Shareholder Resources/Share Swap.
- Expanded global intellectual property protection to 314 patents, with 165 patents granted and 149 applications worldwide as of June 30, 2021.
Financial Results
Operating revenue for the second quarter of fiscal 2021 was NT$160.2 million (US$5.7 million), a 1,260.2% increase compared to NT$11.8 million (US$0.4 million) in the second quarter of fiscal 2020. Operating expenses for the second quarter of fiscal 2021 was NT$251.7 million (US$9.0 million), a 6.2% decrease compared to NT$268.4 million (US$9.1 million) in the second quarter of fiscal 2020. Net loss for the second quarter of fiscal 2021 was NT$75.5 million (US$2.7 million), compared to a loss of NT$242.4 million (US$8.2 million) in the second quarter of 2020, or a net loss of NT$0.66 (US$0.02) per share for the second quarter of fiscal 2021, compared to a net loss of NT$3.28 (US$0.11) per share for the second quarter of fiscal 2020.
The Company’s cash and cash equivalents were NT$696.7 million (US$25.0 million) as of June 30, 2021, compared to NT$1,342.7 million (US$47.8 million) as of December 31, 2020.
Financial Summary
Selected Consolidated Balance Sheet Data
|
|
|
December 31, 2020
|
|
|
June 30, 2021
|
|
|
|
|
NT$000
|
|
|
US$000
|
|
|
NT$000
|
|
|
US$000
|
|
|
Cash and cash equivalents and time deposit
|
|
$
|
1,342,667
|
|
|
$
|
47,816
|
|
|
$
|
696,737
|
|
|
$
|
24,964
|
|
|
Total current assets
|
|
|
1,431,977
|
|
|
|
50,997
|
|
|
|
986,874
|
|
|
|
35,359
|
|
|
Total assets
|
|
|
1,749,461
|
|
|
|
62,303
|
|
|
|
1,330,969
|
|
|
|
47,688
|
|
|
Total current liabilities
|
|
|
348,127
|
|
|
|
12,398
|
|
|
|
327,849
|
|
|
|
11,747
|
|
|
Long-term borrowings
|
|
|
469,076
|
|
|
|
16,705
|
|
|
|
372,809
|
|
|
|
13,357
|
|
|
Total liabilities
|
|
|
886,134
|
|
|
|
31,557
|
|
|
|
775,191
|
|
|
|
27,775
|
|
|
Total equity
|
|
|
863,327
|
|
|
|
30,746
|
|
|
|
555,778
|
|
|
|
19,913
|
|
Selected Consolidated Statements of Operations Data
|
|
|
Three-month periods ended June 30,
|
|
|
Six-month periods ended June 30,
|
|
|
|
|
2020
|
|
|
2021
|
|
|
2020
|
|
|
2021
|
|
|
|
|
NT$000
|
|
|
US$000
|
|
|
NT$000
|
|
|
US$000
|
|
|
NT$000
|
|
|
US$000
|
|
|
NT$000
|
|
|
US$000
|
|
|
Operating revenue
|
|
$
|
11,776
|
|
|
$
|
400
|
|
|
$
|
160,176
|
|
|
$
|
5,739
|
|
|
$
|
23,750
|
|
|
$
|
807
|
|
|
$
|
197,794
|
|
|
$
|
7,087
|
|
|
Operating expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General and administrative expenses
|
|
|
(39,487
|
)
|
|
|
(1,341
|
)
|
|
|
(31,622
|
)
|
|
|
(1,133
|
)
|
|
|
(72,367
|
)
|
|
|
(2,458
|
)
|
|
|
(62,669
|
)
|
|
|
(2,245
|
)
|
|
Research and development expenses
|
|
|
(228,881
|
)
|
|
|
(7,774
|
)
|
|
|
(220,087
|
)
|
|
|
(7,886
|
)
|
|
|
(420,659
|
)
|
|
|
(14,289
|
)
|
|
|
(442,861
|
)
|
|
|
(15,868
|
)
|
|
Total operating expenses
|
|
|
(268,368
|
)
|
|
|
(9,115
|
)
|
|
|
(251,709
|
)
|
|
|
(9,019
|
)
|
|
|
(493,026
|
)
|
|
|
(16,747
|
)
|
|
|
(505,530
|
)
|
|
|
(18,113
|
)
|
|
Loss before income tax
|
|
|
(242,089
|
)
|
|
|
(8,223
|
)
|
|
|
(75,144
|
)
|
|
|
(2,692
|
)
|
|
|
(456,253
|
)
|
|
|
(15,498
|
)
|
|
|
(293,142
|
)
|
|
|
(10,503
|
)
|
|
Income tax expense
|
|
|
(348
|
)
|
|
|
(12
|
)
|
|
|
(363
|
)
|
|
|
(13
|
)
|
|
|
(769
|
)
|
|
|
(26
|
)
|
|
|
(602
|
)
|
|
|
(22
|
)
|
|
Net loss
|
|
$
|
(242,437
|
)
|
|
$
|
(8,235
|
)
|
|
$
|
(75,507
|
)
|
|
$
|
(2,705
|
)
|
|
$
|
(457,022
|
)
|
|
$
|
(15,524
|
)
|
|
$
|
(293,744
|
)
|
|
$
|
(10,525
|
)
|
|
Total other comprehensive loss
|
|
$
|
1,698
|
|
|
$
|
58
|
|
|
$
|
(13,090
|
)
|
|
$
|
(469
|
)
|
|
$
|
(1,808
|
)
|
|
$
|
(61
|
)
|
|
$
|
(21,285
|
)
|
|
$
|
(762
|
)
|
|
Total comprehensive loss
|
|
$
|
(240,739
|
)
|
|
$
|
(8,177
|
)
|
|
$
|
(88,597
|
)
|
|
$
|
(3,174
|
)
|
|
$
|
(458,830
|
)
|
|
$
|
(15,585
|
)
|
|
$
|
(315,029
|
)
|
|
$
|
(11,287
|
)
|
|
Loss per share of common stock
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted loss per share (in dollars)
|
|
$
|
(3.28
|
)
|
|
$
|
(0.11
|
)
|
|
$
|
(0.66
|
)
|
|
$
|
(0.02
|
)
|
|
$
|
(6.18
|
)
|
|
$
|
(0.21
|
)
|
|
$
|
(3.05
|
)
|
|
$
|
(0.11
|
)
|
|
